Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Phase 2
Completed
- Conditions
- LeukemiaChronic Myelogenous LeukemiaChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00493181
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Phase 2
Completed
- Conditions
- LeukemiaSystemic Mastocytosis
- Interventions
- Drug: Ontak (Denileukin Diftitox)
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00493129
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Phase 2
Terminated
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00493454
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00493571
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00492141
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Phase 2
Active, not recruiting
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00492050
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of Single Session Stereotactic Body Radiotherapy
Phase 1
Completed
- Conditions
- Spinal Neoplasms
- Interventions
- Procedure: Stereotactic Body Radiotherapy
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT00492817
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
Phase 1
Completed
- Conditions
- Peritoneal Cancer
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00491855
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Active Surveillance in Prostate Cancer
Completed
- Conditions
- Prostate Cancer
- Interventions
- Behavioral: Survey
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1139
- Registration Number
- NCT00490763
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00491075
- Locations
- 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath